title: Effect of supraspinal antisense oligodeoxynucleotide treatment on delta-opioid receptor mRNA levels in mice.
abstract: Studies in vivo demonstrate that antisense oligodeoxynucleotide (ODN) treatment specifically reduces the functions mediated by numerous central nervous system (CNS) receptors, including opioid receptors. However, the effects of antisense ODN on the opioid receptor mRNA target, itself are rarely examined. In the present study, the effect of supraspinal antisense ODN administration on delta-opioid receptor (DOR) mRNA levels in selected CNS regions, was investigated in mice. ODN targeting a 20-nucleotide sequence of the DOR mRNA transcript was administered by intracerebroventricular (i.c.v.) injection twice daily for 3 days. First, to confirm that antisense ODN treatment decreases DOR function in this system, antinociception produced by DOR-selective agonist [D-Ala2]deltorphin II was assessed on day 4. A 2-fold reduction in [D-Ala2]deltorphin II potency was revealed in antisense ODN-treated mice compared to mice receiving control treatments. DOR mRNA levels in selected CNS regions which either mediate antinociception; medial thalamus (MThal), periaqueductal gray (PAG), frontal cortex (FCtx) and spinal cord (SpC) or exhibit relatively high levels of DOR mRNA; nucleus accumbens (Acb) and caudate-putamen (CPu) were then quantitated by solution hybridization. Levels of DOR mRNA in antisense ODN-treated mice were not different from levels in mice treated with saline vehicle, which ranged from 0.07 pg/microg total RNA in MThal and PAG to 0.26 pg/microg total RNA in CPu. These results are both consistent with previous reports that antisense oligodeoxynucleotide (ODN) treatment down-regulates DOR protein in vivo and indicate that this down-regulation is not associated with altered DOR mRNA levels.
authors.affiliation: Department of Pharmacology, Cornell University Medical College, New York, NY 10021, USA.
authors.forename: C E
authors.initials: CE
authors.lastname: Lee
authors.forename: B
authors.initials: B
authors.lastname: Kest
authors.forename: S
authors.initials: S
authors.lastname: Jenab
authors.forename: C E
authors.initials: CE
authors.lastname: Inturrisi
mesh_terms: D000818:Animals; D001483:Base Sequence; D001921:Brain / Q000378:metabolism*; D002552:Cerebral Ventricles / Q000187:drug effects / Q000502:physiology*; D005625:Frontal Lobe / Q000378:metabolism; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000494:pharmacology*; D009842:Oligopeptides / Q000378:metabolism / Q000494:pharmacology; D009928:Organ Specificity; D010146:Pain; D010487:Periaqueductal Gray / Q000378:metabolism; D012333:RNA, Messenger / Q000096:biosynthesis; D017465:Receptors, Opioid, delta / Q000096:biosynthesis*; D013116:Spinal Cord / Q000378:metabolism*; D013788:Thalamus / Q000378:metabolism; D014158:Transcription, Genetic / Q000187:drug effects*
chemical_list: D016376:Oligonucleotides, Antisense; D009842:Oligopeptides; D012333:RNA, Messenger; D017465:Receptors, Opioid, delta; C060209:deltorphin II, Ala(2)-